Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types.
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types.
复制标题
DOI：
10.1038/s41698-021-00223-x
复制
发表时间：
2021-09-10
影响因子：
7.9
通讯作者：
Kou SC
中科院分区：
文献类型：
--
作者：
Wang F;Yang S;Palmer N;Fox K;Kohane IS;Liao KP;Yu KH;Kou SC
免疫检查点抑制剂在治疗多种类型的癌症方面已经证明了显著的生存益处。然而，它们的免疫相关不良事件（irAEs）尚未在大规模现实世界人群中系统地评估各种癌症类型。为了解决这一差距，我们使用8年来8597万参保人的全国保险索赔数据进行了现实世界的数据分析。我们发现，在所有常用免疫检查点抑制剂治疗的七种癌症类型中，接受免疫疗法的患者发生irae的风险显著增加。治疗初始化6个月后，与匹配的化疗或靶向治疗组相比，接受免疫治疗的患者在治疗的前6个月发生irae的可能性高出1.50-4.00倍（95% CI，下限从1.15到2.16，上限从1.69到20.36），共有92,858例患者。与使用派姆单抗的患者相比，使用纳武单抗的患者发生irae的风险更高。这些结果证实了临床医生需要评估接受免疫治疗的癌症患者的irae作为治疗的一部分。我们的方法可以扩展到以高效和经济的方式在大量人群中描述新疗法的有效性和不良反应。
Immune checkpoint inhibitors have demonstrated significant survival benefits in treating many types of cancers. However, their immune-related adverse events (irAEs) have not been systematically evaluated across cancer types in large-scale real-world populations. To address this gap, we conducted real-world data analyses using nationwide insurance claims data with 85.97 million enrollees across 8 years. We identified a significantly increased risk of developing irAEs among patients receiving immunotherapy agents in all seven cancer types commonly treated with immune checkpoint inhibitors. By six months after treatment initialization, those receiving immunotherapy were 1.50–4.00 times (95% CI, lower bound from 1.15 to 2.16, upper bound from 1.69 to 20.36) more likely to develop irAEs in the first 6 months of treatment, compared to matched chemotherapy or targeted therapy groups, with a total of 92,858 patients. The risk of developing irAEs among patients using nivolumab is higher compared to those using pembrolizumab. These results confirmed the need for clinicians to assess irAEs among cancer patients undergoing immunotherapy as part of management. Our methods are extensible to characterizing the effectiveness and adverse effects of novel treatments in large populations in an efficient and economical fashion.
登录
查看更多内容
影响因子：
6.7
作者：
Franklin, Jessica M.;Schneeweiss, Sebastian
通讯作者：
Schneeweiss, Sebastian
影响因子：
5.3
作者：
Levra, Matteo Giaj;Cotte, Francois-Emery;Chouaid, Christos
通讯作者：
Chouaid, Christos
DOI：
10.1186/s13054-017-1678-1
发表时间：
2017-04-14
期刊：
Critical care (London, England)
影响因子：
--
作者：
Kroschinsky F;Stölzel F;von Bonin S;Beutel G;Kochanek M;Kiehl M;Schellongowski P;Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group
通讯作者：
Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
1.8
作者：
Alhusseini, M.;Samantray, J.
通讯作者：
Samantray, J.